Randomized Trialhigh evidence
Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.
The Lancet. Oncology·November 1, 2026·PMID 42927765
Why it mattersLocally advanced rectal cancer carries a high risk of recurrence despite standard neoadjuvant chemoradiotherapy. This trial provides the first phase 3 evidence that adding immunotherapy to short-course radiotherapy and chemotherapy improves event-free survival, offering a potential new treatment strategy for this population.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled